How Will the Market React to Omeros Corp (OMER) Stock Getting a Bearish Rating

Overall market sentiment has been down on Omeros Corp (OMER) stock lately. OMER receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Omeros Corp has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on OMER!

See Full OMER Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With OMER Stock Today?

Omeros Corp (OMER) stock is trading at $3.46 as of 11:31 AM on Tuesday, Mar 26, a rise of $0.02, or 0.58% from the previous closing price of $3.44. The stock has traded between $3.40 and $3.58 so far today. Volume today is below average. So far 42,893 shares have traded compared to average volume of 555,530 shares. To see InvestorsObserver's Sentiment Score for Omeros Corp click here.

More About Omeros Corp

Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders. Click Here to get the full Stock Report for Omeros Corp stock.